By Marek Poszepczynski and Ailsa Craig, co-investment managers of the International Biotechnology Trust...

We found them in India, Japan, frontier markets, healthcare and the global sector – and here they are…

Download the presentation and listen to the audio from our 'Fantastic growth funds (and were to find them)' conference on 4 November...

IBT remains differentiated to peers, offering exposure to the explosive potential of innovation in healthcare...

The team at BB Healthcare see brighter days ahead despite the best efforts of a sensationalist media to make it feel like doomsday…

“Rarely better exposed to higher quality or more transformational science”...

Dividend culture as we knew it is dead, according to Kepler's David Johnson, but investment trusts offer a solution...

We examine the implications of demographic change for investors...

IBT has had a change of management - but no change of strategy…

The pandemic has boosted secular growth drivers behind healthcare as an investment theme...

Syncona is a unique vehicle offering exposure to high growth, although not without risks...

Audio and presentations from 21 of the UK’s leading investment trust managers…

Download the presentation and listen to the audio from our 'Ideas for your ISA' Spring Conference on 03 March...

Download the presentation and listen to the audio from our 'Ideas for your ISA' Spring Conference on 03 March...

After another set of strong results, we look at how BBH has positioned itself for another year of outperformance…

BBH is a potentially interesting addition to growth portfolios and for investors looking for income.

IBT offers a differentiated way to access strong growth prospects at an undemanding valuation...

View the presentation and listen to the audio from our 'Alternatives for Income Investors' event on 29 September...

Tech has beaten almost everything hands down – but nothing lasts forever. Where else should investors be looking for secular growth themes?

IBT offers a differentiated exposure to a secular growth theme complemented by a solid yield…

BBH has a differentiated approach to a secular-growth theme...

A highly experienced management team and a flexible portfolio of quoted and unquoted biotechnology stocks, with a yield target of 4% of NAV...

We discuss the opportunity as biotech stocks trade at record low valuations, despite strong prospects for the sector...

Five years on from the appointment of a new manager, this US-focused biotech trust has seen its fortunes transformed...

A well-resourced biotechnology fund that has produced annualised returns of +18% under the current manager, offering a yield of 4%...